Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. NORDIC GROWTH MARKET
  5. Attana AB
  6. Summary
    ATANA   SE0010547273

ATTANA AB

(ATANA)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Nordic Growth Market
09/13/2021 09/14/2021 09/15/2021 09/16/2021 09/17/2021 Date
1.142 1.14 1.12 1.118 1.056 Last
184511 242539 215944 927838 660204 Volume
-1.21% -0.18% -1.75% -0.18% -5.55% Change
Estimated financial data (e)
Sales 2020 6,00 M 0,69 M 0,69 M
Net income 2020 -7,50 M -0,86 M -0,86 M
Net cash position 2020 61,3 M 7,02 M 7,02 M
P/E ratio 2020 -
Yield 2020 -
Sales 2021 15,0 M 1,72 M 1,72 M
Net income 2021 -10,7 M -1,23 M -1,23 M
Net cash position 2021 20,3 M 2,32 M 2,32 M
P/E ratio 2021 -
Yield 2021 -
Capitalization 221 M 25,4 M 25,3 M
EV / Sales 2020 26,6x
EV / Sales 2021 13,4x
Nbr of Employees 9
Free-Float 80,7%
More Financials
Company
Attana AB is a Sweden-based biotechnology company specializing in in vitro characterization of molecular interactions mimicking in vivo conditions. The Company develops proprietary label-free biosensors, based on the Quartz Crystal Microbalance (QCM) technology, for biochemical, crude, sera and cell-based assays. Its products and research services are used by pharmaceutical and biotechnology companies to quality... 
More about the company
Ratings of Attana AB
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about ATTANA AB
06/29ATTANA : has obtained CE-IVD Marking for its first products within clinical diag..
AQ
06/29Attana Obtains CE-IVD Marking for Its First Products Within Clinical Diagnost..
CI
06/10ATTANA : and Triolab sign MOU on distribution of Attana's diagnostic offer
AQ
06/10Attana and Triolab Sign MOU on Distribution of Attana's Diagnostic Offer
CI
05/25ATTANA : A recently published study on novel malaria vaccines features Attana's ..
AQ
05/18ATTANA : Per Aniansson appointed new member of Attana's Board
AQ
05/18Attana AB Appoints Per Aniansson as Board Member
CI
05/14ATTANA : will present at Smabolagsdagarna and Erik Penser Bolagsdag
AQ
05/06Attana AB Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
04/22ATTANA : strengthens the operational team with four new employees, including a C..
AQ
03/30Attana Diagnostics Expanded Project Scope with Linnaeus University
CI
03/30Attana Updates on Its CE-IVD certification Regulatory Progress
CI
03/10Attana AB Announces Approval and Initiation of Clinical Phase I/II Study for ..
CI
02/11Attana Collaborates with Linnaeus University Toaccelerate the Development of ..
CI
2020Attana Completes FDA Medical Device Class 1 Listing and Facility Registration
CI
More news
News in other languages on ATTANA AB

- No features available -

More news
Chart ATTANA AB
Duration : Period :
Attana AB Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 1,06 SEK
Average target price 1,65 SEK
Spread / Average Target 56,3%
EPS Revisions
Managers and Directors
Bo Teodor Aastrup Chief Executive Officer & Director
Anders Ulrikson Chief Financial Officer
Arne Nabseth Chairman
Niklas Carlsson Chief Operating Officer & Executive Vice President
Gustav Ingemar Kihlstr÷m Director
Sector and Competitors
1st jan.Capi. (M$)
ATTANA AB-46.12%25
MODERNA, INC.311.65%173 588
GILEAD SCIENCES, INC.22.91%89 785
BIONTECH SE340.60%86 750
REGENERON PHARMACEUTICALS34.93%67 775
WUXI APPTEC CO., LTD.35.75%60 418